Date: 2015-10-20
Type of information: Opening of new premises
Compound: manufacturing and packaging facility in Kaluga, Russia
Company: AstraZeneca (UK)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On October 20, 2015, AstraZeneca announced the opening of its new state-of-the-art manufacturing and packaging facility in Kaluga, Russia, dedicated to the local supply of innovative medicines. In 2011 AstraZeneca announced plans to invest in the construction of a dedicated manufacturing facility in Russia. Four years on, the Company has invested $224m in the development, which is the largest foreign investment in the construction of a new pharmaceutical facility in the country.Commercial production will begin early next year and will focus on final-stage manufacturing, packaging and quality control. The site will become fully operational in 2017 and will produce around 40 million packs and 850 million tablets of some 30 innovative medicines every year. This represents more than 60% of AstraZeneca’s medicines marketed in Russia to treat diseases across the Company’s therapy areas. As a key market for the Group’s emerging markets ambitions, achieving continued growth is a strategic priority for AstraZeneca in Russia where the company achieved Product Sales of more than $200m in 2014. AstraZeneca also invests in clinical research and scientific collaborations in Russia. In 2015, we conducted 27 clinical trials in Russia involving more than 5,000 patients, and have several important collaborations with leading academic and research institutions. As a socially responsible company, AstraZeneca Russia implements initiatives focused on the prevention of non-communicable diseases among young people through the Young Health Programme. The new facility adds to the expansion of AstraZeneca’s global manufacturing capabilities to support the company’s expanding portfolio of medicines and growing demand, following on from the planned biologics manufacturing investments in Sweden (announced in May 2015), the acquisition of a new site in Boulder, Colorado, US (announced in September 2015) and the expansion in Frederick, Maryland, US (announced in November 2014).
Financial terms:
Latest news:
